A phase i trial of bortezomib and interferon-α-2b in metastatic melanoma

Journal of Immunotherapy

Volumn 37, Issue 1, 2014, Pages 55-62

  Markowitz, Joseph ^a   Luedke, Eric A ^a   Grignol, Valerie P ^a   Hade, Erinn M ^a   Paul, Bonnie K ^a   Mundy Bosse, Bethany L ^a   Brooks, Taylor R ^a   Dao, Thao Vi ^a   Kondalasula, Sri V ^a   Lesinski, Gregory B ^a   Olencki, Thomas ^a   Kendra, Kari L ^a   Carson, William E ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Bortezomib; Interferon; Melanoma; Phase I

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BORTEZOMIB; RECOMBINANT ALPHA2B INTERFERON; STAT1 PROTEIN;

ADJUVANT THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; COHORT ANALYSIS; CONFUSION; DEHYDRATION; DEPRESSION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FAINTNESS; FATIGUE; FEMALE; FEVER; HUMAN; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; INSOMNIA; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; METASTATIC MELANOMA; MIDDLE AGED; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OVERALL SURVIVAL; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; PROTEINURIA; SENSORY NEUROPATHY; TREATMENT RESPONSE; VERY ELDERLY; WEAKNESS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CYTOKINES; FEMALE; HUMANS; INTERFERON-ALPHA; LEUKOCYTES, MONONUCLEAR; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PYRAZINES; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84890958467     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000009     Document Type: Article

References (42)

1. Linos E, Swetter SM, Cockburn MG, et al. Increasing burden of melanoma in the United States. J Invest Dermatol. 2009;129: 1666-1674.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62: 10-29.
3. Atkins MB, Kunkel L, Sznol M, et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 2000;6(suppl 1):S11-S14.
4. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17: 2745-2751. (Pubitemid 29415231)
5. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363: 711-723.
6. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364: 2507-2516.
7. Lesinski GB, Raig ET, Guenterberg K, et al. IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosis. Cancer Res. 2008;68: 8351-8360.
8. Dalton WS. The proteasome. Semin Oncol. 2004;31:3-9; discussion 33. (Pubitemid 40164924)
9. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res. 2008;14: 1649-1657. (Pubitemid 351469448)
10. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59: 2615-2622. (Pubitemid 29269108)
11. Ling YH, Liebes L, Jiang JD, et al. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res. 2003;9: 1145-1154. (Pubitemid 36323724)
12. Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res. 2002;8: 2505-2511. (Pubitemid 34856332)
13. Hamilton AL, Eder JP, Pavlick AC, et al. Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J Clin Oncol. 2005;23: 6107-6116.
14. Markovic SN, Geyer SM, Dawkins F, et al. A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer. 2005;103: 2584-2589. (Pubitemid 40800538)
15. Thyrell L, Erickson S, Zhivotovsky B, et al. Mechanisms of Interferon-alpha induced apoptosis in malignant cells. Oncogene. 2002;21: 1251-1262. (Pubitemid 34185242)
16. Lesinski GB, Benninger K, Kreiner M, et al. Bortezomib pretreatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cells. Cancer Immunol Immunother. 2009;58: 2031-2037.
17. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14: 7-17. (Pubitemid 26019991)
18. Zimmerer JM, Lehman AM, Ruppert AS, et al. IFN-alpha-2binduced signal transduction and gene regulation in patient peripheral blood mononuclear cells is not enhanced by a dose increase from 5 to 10 megaunits/m2. Clin Cancer Res. 2008;14: 1438-1445. (Pubitemid 351413927)
19. Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol. 2004;22: 2108-2121. (Pubitemid 41095144)
20. Lesinski GB, Kondadasula SV, Crespin T, et al. Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy. J Natl Cancer Inst. 2004;96: 1331-1342. (Pubitemid 39264122)
21. Fleisher TA, Dorman SE, Anderson JA, et al. Detection of intracellular phosphorylated STAT-1 by flow cytometry. Clin Immunol. 1999;90: 425-430. (Pubitemid 29159629)
22. Kaplan E, Meier P. Nonparametric estimationfrom incomplete observations. J Am Stat Assoc. 1958;53: 457-481.
23. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc A. 1972;135: 185-207.
24. Williams RL. A note on robust variance estimation for clustercorrelated data. Biometrics. 2000;56: 645-646. (Pubitemid 30422662)
25. McCullagh P, Nelder J. Generalized Linear Models. 2nd ed. London: Chapman & Hall/CRC Press; 1989.
26. Cole BF, Gelber RD, Kirkwood JM, et al. Quality-of-lifeadjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1996;14: 2666-2673. (Pubitemid 26329650)
27. Creagan ET, Ahmann DL, Frytak S, et al. Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analyses. Cancer. 1987;59: 638-646.
28. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and lowdose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000;18: 2444-2458. (Pubitemid 30415832)
29. Kirkwood JM,Manola J, Ibrahim J, et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004;10: 1670-1677. (Pubitemid 38435557)
30. Kim KB, Sosman JA, Fruehauf JP, et al. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol. 2012;30: 34-41.
31. Frankland-Searby S, Bhaumik SR. The 26S proteasome complex: an attractive target for cancer therapy. Biochim Biophys Acta. 2012;1825: 64-76.
32. Su Y, Amiri KI, Horton LW, et al. A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets. Clin Cancer Res. 2010;16: 348-357.
33. Croghan GA, Suman VJ, Maples WJ, et al. A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study. Cancer. 2010;116: 3463-3468.
34. Armeanu S, KruschM, Baltz KM, et al. Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma. Clin Cancer Res. 2008;14: 3520-3528.
35. Ames E, HallettWH, Murphy WJ. Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition. Clin Exp Immunol. 2009;155: 504-513.
36. Hu W, Zheng RR, Cui HX, et al. Effects of bortezomib in sensitizing human prostate cancer cell lines to NK-mediated cytotoxicity. Asian J Androl. 2012;14: 695-702.
37. Iwata S, Yano S, Ito Y, et al. Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection. Int J Cancer. 2011; 129: 2263-2273.
38. Lundqvist A, Abrams SI, Schrump DS, et al. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res. 2006; 66: 7317-7325. (Pubitemid 44197714)
39. Shi J, Tricot GJ, Garg TK, et al. Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. Blood. 2008;111: 1309-1317. (Pubitemid 351213417)
40. Hallett WH, Ames E, Motarjemi M, et al. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J Immunol. 2008;180: 163-170.
41. Lundqvist A, Berg M, Smith A, et al. Bortezomib treatment to potentiate the anti-tumor immunity of ex-vivo expanded adoptively infused autologous natural killer cells. J Cancer. 2011;2: 383-385.
42. Lundqvist A, Yokoyama H, Smith A, et al. Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells. Blood. 2009; 113: 6120-6127.